Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule of Deferred Tax Assets and Liabilities (Details)

v3.25.1
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Net operating loss carry forward – Federal $ 7,566,071 $ 6,012,941
Net operating loss carry forward – State 2,074,542 1,672,436
Stock compensation expense 2,794,226 3,453,799
Depreciation and other 238 999
Purchased in-process R&D 2,477,193 2,500,562
Federal orphan drug credits 1,209,202 1,202,955
Capitalized research and development costs 3,781,193 2,795,379
Start-up expenditures and amortization
Total non-current deferred tax assets 19,902,665 17,639,071
Valuation allowance for deferred tax assets (19,902,665) (17,639,071)
Total deferred tax assets
Intangible asset
Total non-current deferred tax liabilities
Total deferred tax asset (liability)